Zhejiang Huakang Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 605077.SS

Zhejiang Huakang Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2023: USD 143.92 M

Zhejiang Huakang Pharmaceutical Co., Ltd. Current Liabilities is USD 143.92 M for the year ending December 31, 2023, a 29.06% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Zhejiang Huakang Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2022 was USD 111.51 M, a 55.48% change year over year.
  • Zhejiang Huakang Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2021 was USD 71.72 M, a 23.40% change year over year.
  • Zhejiang Huakang Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2020 was USD 58.12 M, a 0.82% change year over year.
  • Zhejiang Huakang Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2019 was USD 57.65 M, a -24.77% change year over year.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
SV Wall Street
Shanghai Stock Exchange: 605077.SS

Zhejiang Huakang Pharmaceutical Co., Ltd.

CEO Mr. Deshui Chen
IPO Date Feb. 9, 2021
Location China
Headquarters No.18, Huagong Road
Employees 1,350
Sector Consumers Staples
Industries
Non-Alcoholic Beverages Alcoholic Beverages Biofuel Chemicals & Advanced Materials Food & Beverages Glass Plastics Soft Drinks & Sodas
Description

Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols worldwide. Its products include xylitol, a polyol with close to sugar sweetness; sorbitol, a sugar alcohol being white crystal powder; maltitol, a sugar alcohol; xylose that is used in xylitol production; and L-arabinos, which can be used as sucrose replacement or additives. The company is based in Kaihua County, China.

StockViz Staff

February 2, 2025

Any question? Send us an email